EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab

Lucie Poisson iD, Quentin Le Hingrat, Fanny Lermechain, Fabienne Tombette, Henri Jullien, Jean-Christophe Plantier, Elodie Alessandri-Gradt iD

Journal of Medical Virology · 2026-04 · 98 (4)

DOI: 10.1002/jmv.70911 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 11.04.2026. Verfasst von Lucie Poisson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de Virologie, CHU de Rouen, Rouen, France. Hauptthemen laut MEDLINE: HIV-1, Antibodies, Monoclonal, Anti-HIV Agents. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Santé Publique France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study assessed the phenotypic susceptibility of non group‐M human immunodeficiency virus type 1 (HIV‐1/non‐M) clinical isolates to ibalizumab, the first‐in‐class long‐acting CD4‐directed post‐attachment inhibitor. Thirty isolates were tested: 1 HIV‐1/M (reference strain BRU.HXB2), 2 HIV‐1/N, 26 HIV‐1/O and 1 HIV‐1/P. A phenotypic in vitro assay was performed by pre‐incubating peripheral blood mononuclear cells with ibalizumab, (1–10 000 ng/mL), then infected and incubated before quantifying viral load with RT‐PCR. IC 50 , maximum percent inhibition (MPI), and fold change (FC) were calculated. Potential N ‐glycosylation sites (PNGS) in the V5 loop, V2 loop length and the side chain at position 375 were investigated. Ibalizumab inhibited 22 HIV‐1/O and 1 HIV‐1/N strains, with a median IC 50 of 0.0413 (range: 6.19E10 −11 ; 16.8) ng/mL and a median MPI of 96.9 (range: 68.4; 99.3)%. The HIV‐1/P strain displayed potential resistance (IC 50 > 10 000 ng/mL; MPI < 25%). Interpretable results were not obtained for 4 HIV‐1/O and 1 HIV‐1/N strains under standardization criteria. PNGS numbers in the V5 loop ranged from 0 to 4 in tested isolates. Ibalizumab showed in vitro activity against all validated HIV‐1/O and HIV‐1/N isolates, whereas the HIV‐1/P strain exhibited potential natural resistance. No relationship was observed between PNGS number and susceptibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Antibodies, MonoclonalAnti-HIV AgentsHumansInhibitory Concentration 50Leukocytes, MononuclearViral LoadHIV InfectionsMicrobial Sensitivity TestsPhenotypeGlycosylation

Stichwörter der Autor:innen

HIVanti‐retrovirus drugentry inhibitorsgenetic variabilityresistance

Substanzen

ibalizumabAntibodies, MonoclonalAnti-HIV Agents

Autor:innen und Institutionen

  • Laboratoire de Virologie, CHU de Rouen, Rouen, France.
  • Université Paris Cité, INSERM UMR1137, IAME, Paris, France.
  • AP-HP Nord, Département de Vriologie, CHU Bichat Claude-Bernard, Paris, France.
  • Theratechnologies Inc., Montreal, Quebec, Canada.
  • DYNAMICURE UMR1311, CHU Rouen, Département de Virologie, UnivRouen Normandie, Université de Caen Normandie, INSERM, Normandie University, Rouen, France.

ORCID-Profile: Lucie Poisson, Elodie Alessandri-Gradt

Förderung

  • Santé Publique France

Zitieren

APA

Poisson, L., Hingrat, Q. L., Lermechain, F., Tombette, F., Jullien, H., Plantier, J. C., & Alessandri-Gradt, E. (2026). HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab. Journal of Medical Virology, 98(4). https://doi.org/10.1002/jmv.70911

Vancouver

Poisson L, Hingrat QL, Lermechain F, Tombette F, Jullien H, Plantier JC, et al. HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab. Journal of Medical Virology. 2026;98(4). doi:10.1002/jmv.70911

BibTeX
@article{Poisson2026,
  author = {Poisson, Lucie and Hingrat, Quentin Le and Lermechain, Fanny and Tombette, Fabienne and Jullien, Henri and Plantier, Jean-Christophe and Alessandri-Gradt, Elodie},
  title = {HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {4},
  doi = {10.1002/jmv.70911}
}
Kostenlos starten →